Author

Christopher J. Bettacchi

Observed names: CHRISTOPHER BETTACCHI, Chris Bettacchi, Christopher Bettacchi, Christopher J Bettacchi

Observed institutions: Queen Mary University of London, Baylor University Medical Center, University of Alabama at Birmingham, National Center for Global Health and Medicine, Hôpital Saint-Antoine, Central Research Institute of Epidemiology, Hôpital Européen, Baylor Scott & White Health

ORCID: 0000-0003-1148-6985

Observed ORCID: 0000-0003-1148-6985

OpenAlex ID: A5030032271

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

2020 · Chloe Orkin, Keikawus Arasteh, et al. · New England Journal of Medicine · 488

PDF

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

2019 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 98

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

2021 · Graham H R Smith, W Keith Henry, et al. · Open Forum Infectious Diseases · 61

PDF

The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19

2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60

PDF

Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial

2021 · Jean-Michel Molina, Yazdan Yazdanpanah, et al. · The Lancet HIV · 48

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

2023 · Chloe Orkin, Jean-Michel Molina, et al. · The Lancet HIV · 34

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

2022 · ACTIV-3/TICO Study Group*, Christina Barkauskas, et al. · Annals of Internal Medicine · 31

PDF

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

2019 · Scott L Letendre, Anthony Mills, et al. · Journal of Antimicrobial Chemotherapy · 30

PDF

A comparison of 3 metrics to identify health care-associated infections

2012 · Alan M. Stamm, Christopher J. Bettacchi · American Journal of Infection Control · 30

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine

2021 · Jean-Michel Molina, Yazdan Yazdanpanah, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 26

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

2026 · Amy E Colson, Anthony M Mills, et al. · The Lancet · 20

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

2023 · Samuel M Brown, Christina E Barkauskas, et al. · The Lancet Respiratory Medicine · 19

PDF

Success of staged revision reverse total shoulder arthroplasty in eradication of periprosthetic joint infection

2022 · Eddie Y. Lo, Alvin Ouseph, et al. · Journal of Shoulder and Elbow Surgery · 18

Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19

2024 · Neil R Aggarwal, Jacquie Nordwall, et al. · Clinical Infectious Diseases · 15

PDF

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

2026 · Jürgen K Rockstroh, Sheetal Kassim, et al. · The Lancet HIV · 10

Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks

2020 · Jean‐Michel Molina, Yazdan Yazdanpanah, et al. · Universidad de Chile · 9

1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF

2023 · Mehri McKellar, Paula Teichner, et al. · Open Forum Infectious Diseases · 4

PDF

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

2023 · Tomas O Jensen, Greg A Grandits, et al. · The Journal of Infectious Diseases · 4

PDF

Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial

2026 · Amy E Colson, Princy N Kumar, et al. · The Lancet · 3

VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results

2025 · Peter A Leone, Alejandro Ferro, et al. · The Journal of Infectious Diseases · 3

PDF

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

2020 · Graham Smith, Keith Henry, et al. · Open Forum Infectious Diseases · 2

Islatravir safety analysis through week 48 from a phase 2 trial in treatment naive adults with HIV-1 infection

2020 · Edwin DeJesus, Jean‐Michel Molina, et al. · Universidad de Chile · 2

P-369. Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) after ISL Dose Reduction from 0.75 mg: Week 48 Results from an Open-Label Phase 3 Study

2026 · Rosie Mngqibisa, Sheetal Kassim, et al. · Open Forum Infectious Diseases · 1

The Role of Feral Swine in Human Aortic Infection With Brucella Species

2023 · John F. Eidt, Megan E. Parrott, et al. · Vascular and Endovascular Surgery · 1

Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy–Suppressed Viral Load

2026 · Tanaya R Vaidya, Till Geib, et al. · The Journal of Infectious Diseases

Works count: 27

Citation count: 1,015

H-index: 14

I10-index: 15